Diabetes Mellitus, Type 2NCT06862180
Effect of Meal Replacement Therapy on Glucose Control and Metabolic Parameters in Patients With Uncontrolled Diabetes
A study testing Meal replacement therapy in people with Diabetes Mellitus, Type 2, run by Hospital Universiti Sains Malaysia at 1 site in Malaysia.
Trial summary
To evaluate the effect of meal replacement therapy on glucose control and other metabolic parameters in patients with uncontrolled type 2 diabetes. Methodology: This is an open-label, prospective, randomized control trial study. Study duration. August 2023 - March 2026. Study location. Read more about this study
- Who is it for?
- Ages 30 to 65 years
- Conditions the study is for
- Diabetes Mellitus, Type 2
- What is being tested?
- Meal replacement therapy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 108 participants
- Where
- 1 siteMalaysia
- Study dates
- 1 Nov 2024to Mar 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients between ≥ 30 to ≤ 65 years old
- Diagnosed as having type 2 diabetes mellitus base on CPG Malaysia Clinical Practice Guidelines (CPG) for Type 2 Diabetes Mellitus (T2DM) 6th edition 2020.
- On oral hypoglycaemic agent(s)
- HbA1c 7- 10 % (result 3 months from the date of recruitment)
- Agree not to take other beverages, herbal or nutritional supplements for the duration of the study.
Who cannot join
- Severe diabetic complication(s) including end-stage renal disease and proliferative retinopathy.
- Pregnancy or plan to get pregnant during the study period
- Newly diagnosed diabetic less than 3 months from the date of recruitment
- Currently involve in any weight loss program
- Currently consuming any meal replacement product
- Patients with chronic kidney disease with eGFR ≤ 25 ml/min.
- Patients with advanced liver disease, such as non-alcoholic steatohepatitis (NASH) with significant fibrosis (e.g., liver stiffness measurement > 9.5 kPa by FibroScan) or cirrhosis.
- Patients with significantly elevated liver enzymes (e.g., ALT or AST ≥ 3 times the upper limit of normal), which may indicate more severe liver damage.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Malaysia1 site, 1 recruiting
- Recruiting
Hospital Universiti Sains Malaysia
Kubang Kerian, Kelantan, 16150
kanmani kumaran, MD, +60135125136, kanmanikumaran@yahoo.com
Nani Draman, Masters, +601115184421, drnani@usm.my
About this study
Official title: The Effect of Meal Replacement Therapy on Glucose Control and Other Metabolic Parameters in Patients With Uncontrolled Type 2 Diabetes on Oral Hypoglycemic Agents: A Randomized Controlled Trial
To evaluate the effect of meal replacement therapy on glucose control and other metabolic parameters in patients with uncontrolled type 2 diabetes.
Methodology:
This is an open-label, prospective, randomized control trial study. Study duration. August 2023 - March 2026. Study location. This study will be conducted at the Klinik Rawatan Keluarga and diabetes clinic Hospital Universiti Sains Malaysia.
Source Reference :
People with type 2 diabetes mellitus attending the Hospital Universiti Sains Malaysia.
Study source population :
People with type 2 diabetes mellitus attended Klinik Rawatan Keluarga and diabetes clinic Hospital Universiti Sains Malaysia during the study period.
Read the detailed description
General objective To determine the effect of Contro Eazy NOW (CEN) as meal replacement therapy on HbA1c, fasting plasma glucose, fasting lipid profile, body mass index (BMI) and body composition in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents vs control group.
Hypotheses
- There are significant improvement in HbA1c over a 12-week period between type 2 diabetes mellitus patients taking meal replacement Contro Eazy Now vs the control group (between-group).
- There are significant improvement in HbA1c among type 2 diabetes mellitus patients at baselines and 12-week after taking meal replacement Contro Eazy Now (within-group).
- There are significant improvements in fasting plasma glucose, fasting lipid profile, body mass index (BMI), blood pressure body composition (muscle mass(kg), fat mass (kg), fat percentage (%) and diabetes quality of life over 12-weeks between type 2 diabetes mellitus patients taking meal replacement Contro Eazy Now vs control group (between-group).
- There are significant improvements in fasting plasma glucose, fasting lipid profile, body mass index (BMI), blood pressure, body composition (muscle mass(kg), fat mass (kg), fat percentage (%) and diabetes quality of life at baselines and 12-week after taking meal replacement Contro Eazy Now? (within-group).
Study procedure Participants will be recruited from KRK. Potential participants will be identified from the case notes of patients or being referred by the medical officers in charge. Participants will be screened to determine their eligibility criteria. Those who are willing to participate in this study will be given information regarding the study. Informed consent will be obtained. Their latest blood result within the last 3 months will be checked such as hemoglobin A1c (HbA1c), Liver function test (LFT), renal function test (RFT). If there is no blood result within the last 3 months, blood will be taken and sent to the private lab.
If all the inclusion criteria are fulfilled, they will be given an appointment for the next visit for recruitment. During recruitment, the participants' socio-demographic data will be collected, and the medical record will be assessed to fill in their medical and diabetes profiles. They will also answer the Diabetes Quality of Life (Rv-DQoL) questionnaire. The physical examination includes measurement of height, weight, calculated Body Mass Index (BMI), body composition (muscle mass, fat mass and fat percentage) and blood pressure during sitting will be done. Blood taking 8ml of fasting venous blood will be taken for measurement of hemoglobin A1c (HbA1c), fasting blood sugar(FBS), full blood count(FBC), renal function test(RFT), liver function test(LFT) and fasting lipid profile(FLP) as a baseline.
All participants were advised not to consume any special supplement or other replacement meal throughout the study. They then will be given an appointment date for visit 2 for randomization.
During visit 2, The participants will be randomized to either intervention or control group. Both groups will receive diet consultation and dietary assessment using a 24-hour diet recall form from the dietitian in the study team at the Dietetic Clinic, Hospital USM. Those in the intervention group will receive diet consultation and meal replacement therapy (Contro Eazy Now (CEN)). The control group will get a diet consultation.
The participants will be seen 6 weeks after taking the product. During this visit, they will be assessed for any side effects or adverse events and compliance with meal replacement product (food record form). Blood pressure, weight, height, calculated Body Mass Index (BMI) and body composition (muscle mass, fat mass and fat percentage) also will be measured. Supply of Contro Eazy Now (CEN) will be given for another 6 weeks for the intervention group. For the control group, blood pressure, weight, height, calculated Body Mass Index (BMI) and body composition (muscle mass, fat mass and fat percentage) also will be measured.
Lastly, the participants will be assessed in week 12. During this visit, the same measurement will be taken as visit 1, including answering the Diabetes Quality of Life (Rv-DQoL) Questionnaires. Adverse events and compliance will be assessed. Blood taking 8ml of fasting venous blood same as baseline will be taken for measurement of HbA1c, FBS, FBC, RFT, LFT and FLP.
The duration for visit 1 and visit 4 (at 12 weeks) is about 50-60 minutes for each visit since it will involve blood taking procedure. Duration for visit 2 and 3 (at 6 weeks) is about 30 minutes since it will not involve blood taking.
Meal replacement arm group. At baseline, both the meal replacement and control group will receive diet consultation from a research Dietician. On top of that, the MR group will receive a meal replacement product (Contro Eazy Now) to replace one meal daily for 5 days a week. Participants in the MR group then will be briefed about meal replacement therapy using Contro Eazy Now (CEN) covering its benefits (on glucose control, weight, body composition and quality of life), dosage, method of preparation and suggested meal replacement time. The meal replacement time suggested by the Dietitian must be agreed by participants first, to allow good compliance with meal replacement therapy.
The duration of the intervention will be 12 weeks. All participants are required to return to the clinic in the 6th and 12th week for a post-intervention assessment. Dietary compliance towards advice on diabetic diet and meal replacement therapy given at baseline will be assessed on the 6th and 12th week intervention in 30 minutes follow up session.
Control group Participants will receive one session of dietary consultation at baseline. The 45 to 60 minutes session will be conducted on a one-on-one basis by a research Dietitian. The dietary consultation session mirrors usual/standard practice for diabetes patients at Dietetic Clinic Hospital USM, including topics on calorie intake and carbohydrate requirements, carbohydrate food sources, carbohydrate exchange counting, sucrose intake, fat intake, Healthy Food Plate Malaysia, physical activity recommendation, and individualised menu plan.
Upon completion of the dietary consultation session, participants in the control group will be advised to continue their daily lives and routine medical care without extra intervention.
They will be given a 24-hour diet record form to record the 24-hour diet recall before coming in for follow-up at 6-week and 12-week.
The duration of the intervention will be 12-weeks, the same as MR group. Dietary compliance advice on diabetic diet given at baseline FRF will be assessed on the 6th and 12th week.
Follow up There will be two follow-ups during this study. 1st follow-up will be on the 6th week and 2nd follow-up (final follow-up) will be during 12th week of the study.
During the 6th week follow-up, participants will be checked for their weight, height, calculated Body Mass Index (BMI), body composition and Compliance Form, any adverse effect will be documented and collect the balance of six-weeks supplements. During this visit also the participants will be asked to bring their Food Record Form, and the researcher will check the form before handing over the balance of 6-weeks MR product.
A final visit (12th week) to the clinic will be conducted on the 12th week. During these visits, assessment of the outcome measures will be carried out to determine the effect of meal replacement interventions.
- Conditions
- Diabetes Mellitus, Type 2
- Being tested
- Meal replacement therapy
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Meal replacement therapyOther
Also called Contro Eazy Now.
A serving of Contro Eazy Now is equivalent to 5 scoops (50g) contains 26.5g of carbohydrate, 10g of protein and 8.9g of fat. It supplies 215kcal of energy per serving
| Study group | Role | What they receive |
|---|---|---|
| Intervention group | Experimental | Meal replacement therapy . Receives: Other: Meal replacement therapy |
| Control group | No intervention | Dietary consultation. |
What is being measured
The primary outcome is the main question the study is designed to answer.
To compare changes and differences of HbA1c over a 12-week period in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement vs control group.
The HbA1c test reflects the average blood glucose levels by measuring the percentage of glycated hemoglobin (hemoglobin bound with glucose) and is an important indicator of long term blood sugar control. The HbA1c results are reported as a percentage (%) of glycated hemoglobin. The target HbA1C level for most diabetic individuals is typically below 7% to reduce the risk of diabetes-related complications.
Measured: 12 weeks
Secondary outcomes (12)
To compare changes and differences in fasting plasma glucose, in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement vs control group.
A fasting blood glucose test measures the amount of glucose in blood after a period of fasting (usually 8-12 hours). Fasting plasma glucose will be measured in millimoles per liter.
(mmol/L). The participants fasts overnight, usually for 8 hours before the test.
Measured: 12 weeks
To compare changes and differences in fasting lipid profile in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement vs control group.
A fasting lipid profile (or lipid panel) measures the levels of various types of fats in the blood, including Total Cholesterol, High-Density Lipoprotein (HDL) Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol and triglycerides. Fasting lipid profile will be measure in millimoles per liter (mmol/L). Patients are usually advised to fast overnight, avoiding food and drinks (except water) for 8 hours before the test.
Measured: 12 weeks
To compare changes and differences in body mass index (BMI), in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement vs control group.
BMI is a calculated measure of a person's body weight (in kilograms) divided by the square of their height (in meters). BMI is a quick, low-cost, and reliable screening measure for underweight, overweight, or obesity.
Measured: 12 weeks.
To compare changes and differences in body composition (muscle mass(kg), in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement vs control group.
Body composition is the body's amount of fat relative to fat-free mass. It will be measured in kilogram (kg).
Measured: 12 weeks
To compare changes and differences in diabetes quality of life in patients with type 2 diabetes mellitus in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement vs control group.
In this study, investigatiors will use the Malay version of the revised Diabetes Quality of Life (Rv-DQoL) adapted from the Diabetes Quality of Life (DQoL) questionnaire. DQoL was intended to be used for evaluating the quality of life specifically related to T2DM and was made up of three major domains, namely, (i) Diabetes Life Satisfaction (QoL Satisfy), Disease Impact Scale (QoL Impact), and (iii) Disease-Related Worries Scale (QoL Worry), and one general question to reflect self-rating of overall general health. All items in the QoL Satisfy domain are scored on a five-point scale, ranging from 1 (very satisfied) to 5 (very dissatisfied), whereas the items in the QoL Impact and QoL Worry are scored on a five-point scale, ranging from 1 (never) to 5 (all the time).
Measured: 12 weeks.
To compare changes and differences in fasting plasma glucose, in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement (within group).
A fasting blood glucose test measures the amount of glucose in blood after a period of fasting (usually 8-12 hours). Fasting plasma glucose will be measured in millimoles per liter.
(mmol/L). The participants fasts overnight, usually for 8 hours before the test.
Measured: 12 weeks
To compare changes and differences in fasting lipid profile in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement (within group).
A fasting lipid profile (or lipid panel) measures the levels of various types of fats in the
Measured: 12 weeks
To compare changes and differences in body mass index (BMI), in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement within group.
BMI is a calculated measure of a person's body weight (in kilograms) divided by the square of their height (in meters). BMI is a quick, low-cost, and reliable screening measure for underweight, overweight, or obesity.
Measured: 12 weeks.
To compare changes and differences in body composition (muscle mass(kg), fat mass (kg) and fat in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement within group.
Body composition is the body's amount of fat relative to fat-free mass.
Measured: 12 weeks.
To compare changes and differences in diabetes quality of life in patients with type 2 diabetes mellitus in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement within group.
In this study investigators will use the Malay version of the revised Diabetes Quality of Life (Rv-DQoL) adapted from the Diabetes Quality of Life (DQoL) questionnaire. DQoL was intended to be used for evaluating the quality of life specifically related to T2DM and was made up of three major domains, namely, (i) Diabetes Life Satisfaction (QoL Satisfy), Disease Impact Scale (QoL Impact), and (iii) Disease-Related Worries Scale (QoL Worry), and one general question to reflect self-rating of overall general health. All items in the QoL Satisfy domain are scored on a five-point scale, ranging from 1 (very satisfied) to 5 (very dissatisfied), whereas the items in the QoL Impact and QoL Worry are scored on a five-point scale, ranging from 1 (never) to 5 (all the time).
Measured: 12 weeks
To monitor meal replacement related adverse events in participants who are in the intervention group over the study period.
Participants will be asked to report any complications or adverse effects to the research team, and any occurrence of adverse events due to trial intervention will be reported to the clinic and attended to by a medical doctor from the research team if any treatment is needed. The safety evaluation will be determined by the incidence of adverse events and an adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical drug, and which did not necessarily have a causal relationship to the treatment.
Adverse event may include:
The significant worsening of the disease or symptoms of the disease under investigation following administration of the drug.
Any undercurrent illness with an onset after administration of the drug. Exacerbation (i.e increase in frequency or intensity) of a pre-existing condition or event.
Measured: 12 weeks
To compare changes and differences in body composition fat mass (kg) in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement vs control group.
Body composition is the body's amount of fat relative to fat-free mass. It will be measured in kilogram (kg)
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Mar 2025
- Study start1 Nov 2024
- Primary completionMay 2025 (estimated)
- Study completionMar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes Mellitus, Type 2Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The participants then will be randomized to either intervention or control group. Both groups will receive diet consultation and dietary assessment using a 24-hour diet recall form from Dietitian in study team at Dietetic Clinic, Hospital USM. Those in the intervention group will receive diet consultation and meal replacement therapy Contro Eazy Now (CEN). The control group will get diet consultation.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 108 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospital Universiti Sains Malaysia
- Sponsor type
- University, hospital or other
- Collaborators
- Ethos Healthcare Sdn Bhd company
- Responsible party
- Principal investigator, Kanmani Kumaran, Hospital Universiti Sains Malaysia
- Investigators
- Nani Draman, Masters, Principal investigator, ProfessorSiti suhaila, Masters, Study chair, DRNG Ying ying, Masters, Study chair, DRNajib Majdi, PHD, Study chair, ProfKhairun Nisah Ibrahim, Masters, Study chair, MissKanmani Kumaran, MD, Study chair, DR
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06862180
- Sponsor's protocol ID
- RSCH ID-23-06002-VHE.
- Status last verified
- Mar 2025
- First submitted
- 18 Jan 2025
- Last updated
- 6 Mar 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Meal Replacement Therapy on Glucose Control and Other Metabolic Parameters in Patients With Uncontrolled Type 2 Diabetes on Oral Hypoglycemic Agents: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06862180
- Acronym / sponsor ID
- RSCH ID-23-06002-VHE.
- Conditions
- Diabetes Mellitus, Type 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 108 participants (estimated)
- Lead sponsor
- Hospital Universiti Sains MalaysiaUniversity, hospital or other
- Collaborators
- Ethos Healthcare Sdn Bhd company
- Study start
- 1 Nov 2024 (actual)
- Primary completion
- May 2025 (estimated)
- Study completion
- Mar 2026 (estimated)
- First posted
- 6 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the effect of meal replacement therapy on glucose control and other metabolic parameters in patients with uncontrolled type 2 diabetes.
Methodology:
This is an open-label, prospective, randomized control trial study. Study duration. August 2023 - March 2026. Study location. This study will be conducted at the Klinik Rawatan Keluarga and diabetes clinic Hospital Universiti Sains Malaysia.
Source Reference :
People with type 2 diabetes mellitus attending the Hospital Universiti Sains Malaysia.
Study source population :
People with type 2 diabetes mellitus attended Klinik Rawatan Keluarga and diabetes clinic Hospital Universiti Sains Malaysia during the study period.
Detailed description
General objective To determine the effect of Contro Eazy NOW (CEN) as meal replacement therapy on HbA1c, fasting plasma glucose, fasting lipid profile, body mass index (BMI) and body composition in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents vs control group.
Hypotheses
- There are significant improvement in HbA1c over a 12-week period between type 2 diabetes mellitus patients taking meal replacement Contro Eazy Now vs the control group (between-group).
- There are significant improvement in HbA1c among type 2 diabetes mellitus patients at baselines and 12-week after taking meal replacement Contro Eazy Now (within-group).
- There are significant improvements in fasting plasma glucose, fasting lipid profile, body mass index (BMI), blood pressure body composition (muscle mass(kg), fat mass (kg), fat percentage (%) and diabetes quality of life over 12-weeks between type 2 diabetes mellitus patients taking meal replacement Contro Eazy Now vs control group (between-group).
- There are significant improvements in fasting plasma glucose, fasting lipid profile, body mass index (BMI), blood pressure, body composition (muscle mass(kg), fat mass (kg), fat percentage (%) and diabetes quality of life at baselines and 12-week after taking meal replacement Contro Eazy Now? (within-group).
Study procedure Participants will be recruited from KRK. Potential participants will be identified from the case notes of patients or being referred by the medical officers in charge. Participants will be screened to determine their eligibility criteria. Those who are willing to participate in this study will be given information regarding the study. Informed consent will be obtained. Their latest blood result within the last 3 months will be checked such as hemoglobin A1c (HbA1c), Liver function test (LFT), renal function test (RFT). If there is no blood result within the last 3 months, blood will be taken and sent to the private lab.
If all the inclusion criteria are fulfilled, they will be given an appointment for the next visit for recruitment. During recruitment, the participants' socio-demographic data will be collected, and the medical record will be assessed to fill in their medical and diabetes profiles. They will also answer the Diabetes Quality of Life (Rv-DQoL) questionnaire. The physical examination includes measurement of height, weight, calculated Body Mass Index (BMI), body composition (muscle mass, fat mass and fat percentage) and blood pressure during sitting will be done. Blood taking 8ml of fasting venous blood will be taken for measurement of hemoglobin A1c (HbA1c), fasting blood sugar(FBS), full blood count(FBC), renal function test(RFT), liver function test(LFT) and fasting lipid profile(FLP) as a baseline.
All participants were advised not to consume any special supplement or other replacement meal throughout the study. They then will be given an appointment date for visit 2 for randomization.
During visit 2, The participants will be randomized to either intervention or control group. Both groups will receive diet consultation and dietary assessment using a 24-hour diet recall form from the dietitian in the study team at the Dietetic Clinic, Hospital USM. Those in the intervention group will receive diet consultation and meal replacement therapy (Contro Eazy Now (CEN)). The control group will get a diet consultation.
The participants will be seen 6 weeks after taking the product. During this visit, they will be assessed for any side effects or adverse events and compliance with meal replacement product (food record form). Blood pressure, weight, height, calculated Body Mass Index (BMI) and body composition (muscle mass, fat mass and fat percentage) also will be measured. Supply of Contro Eazy Now (CEN) will be given for another 6 weeks for the intervention group. For the control group, blood pressure, weight, height, calculated Body Mass Index (BMI) and body composition (muscle mass, fat mass and fat percentage) also will be measured.
Lastly, the participants will be assessed in week 12. During this visit, the same measurement will be taken as visit 1, including answering the Diabetes Quality of Life (Rv-DQoL) Questionnaires. Adverse events and compliance will be assessed. Blood taking 8ml of fasting venous blood same as baseline will be taken for measurement of HbA1c, FBS, FBC, RFT, LFT and FLP.
The duration for visit 1 and visit 4 (at 12 weeks) is about 50-60 minutes for each visit since it will involve blood taking procedure. Duration for visit 2 and 3 (at 6 weeks) is about 30 minutes since it will not involve blood taking.
Meal replacement arm group. At baseline, both the meal replacement and control group will receive diet consultation from a research Dietician. On top of that, the MR group will receive a meal replacement product (Contro Eazy Now) to replace one meal daily for 5 days a week. Participants in the MR group then will be briefed about meal replacement therapy using Contro Eazy Now (CEN) covering its benefits (on glucose control, weight, body composition and quality of life), dosage, method of preparation and suggested meal replacement time. The meal replacement time suggested by the Dietitian must be agreed by participants first, to allow good compliance with meal replacement therapy.
The duration of the intervention will be 12 weeks. All participants are required to return to the clinic in the 6th and 12th week for a post-intervention assessment. Dietary compliance towards advice on diabetic diet and meal replacement therapy given at baseline will be assessed on the 6th and 12th week intervention in 30 minutes follow up session.
Control group Participants will receive one session of dietary consultation at baseline. The 45 to 60 minutes session will be conducted on a one-on-one basis by a research Dietitian. The dietary consultation session mirrors usual/standard practice for diabetes patients at Dietetic Clinic Hospital USM, including topics on calorie intake and carbohydrate requirements, carbohydrate food sources, carbohydrate exchange counting, sucrose intake, fat intake, Healthy Food Plate Malaysia, physical activity recommendation, and individualised menu plan.
Upon completion of the dietary consultation session, participants in the control group will be advised to continue their daily lives and routine medical care without extra intervention.
They will be given a 24-hour diet record form to record the 24-hour diet recall before coming in for follow-up at 6-week and 12-week.
The duration of the intervention will be 12-weeks, the same as MR group. Dietary compliance advice on diabetic diet given at baseline FRF will be assessed on the 6th and 12th week.
Follow up There will be two follow-ups during this study. 1st follow-up will be on the 6th week and 2nd follow-up (final follow-up) will be during 12th week of the study.
During the 6th week follow-up, participants will be checked for their weight, height, calculated Body Mass Index (BMI), body composition and Compliance Form, any adverse effect will be documented and collect the balance of six-weeks supplements. During this visit also the participants will be asked to bring their Food Record Form, and the researcher will check the form before handing over the balance of 6-weeks MR product.
A final visit (12th week) to the clinic will be conducted on the 12th week. During these visits, assessment of the outcome measures will be carried out to determine the effect of meal replacement interventions.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- The participants then will be randomized to either intervention or control group. Both groups will receive diet consultation and dietary assessment using a 24-hour diet recall form from Dietitian in study team at Dietetic Clinic, Hospital USM. Those in the intervention group will receive diet consultation and meal replacement therapy Contro Eazy Now (CEN). The control group will get diet consultation.
| Arm | Type | Receives |
|---|---|---|
| Intervention group | Experimental | Other: Meal replacement therapyMeal replacement therapy . |
| Control group | No intervention | –Dietary consultation. |
Who may qualify
- Ages
- 30 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patients between ≥ 30 to ≤ 65 years old
- Diagnosed as having type 2 diabetes mellitus base on CPG Malaysia Clinical Practice Guidelines (CPG) for Type 2 Diabetes Mellitus (T2DM) 6th edition 2020.
- On oral hypoglycaemic agent(s)
- HbA1c 7- 10 % (result 3 months from the date of recruitment)
- Agree not to take other beverages, herbal or nutritional supplements for the duration of the study.
Key exclusion criteria (8 listed)
- Severe diabetic complication(s) including end-stage renal disease and proliferative retinopathy.
- Pregnancy or plan to get pregnant during the study period
- Newly diagnosed diabetic less than 3 months from the date of recruitment
- Currently involve in any weight loss program
- Currently consuming any meal replacement product
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Meal replacement therapyAlso: Contro Eazy Now.A serving of Contro Eazy Now is equivalent to 5 scoops (50g) contains 26.5g of carbohydrate, 10g of protein and 8.9g of fat. It supplies 215kcal of energy per serving | Other | Intervention group |
Primary outcome
To compare changes and differences of HbA1c over a 12-week period in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement vs control group.
Time frame: 12 weeks
The HbA1c test reflects the average blood glucose levels by measuring the percentage of glycated hemoglobin (hemoglobin bound with glucose) and is an important indicator of long term blood sugar control. The HbA1c results are reported as a percentage (%) of glycated hemoglobin. The target HbA1C level for most diabetic individuals is typically below 7% to reduce the risk of diabetes-related complications.
12 secondary outcomes
To compare changes and differences in fasting plasma glucose, in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement vs control group.
Time frame: 12 weeks
To compare changes and differences in fasting lipid profile in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement vs control group.
Time frame: 12 weeks
To compare changes and differences in body mass index (BMI), in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement vs control group.
Time frame: 12 weeks.
To compare changes and differences in body composition (muscle mass(kg), in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement vs control group.
Time frame: 12 weeks
To compare changes and differences in diabetes quality of life in patients with type 2 diabetes mellitus in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement vs control group.
Time frame: 12 weeks.
To compare changes and differences in fasting plasma glucose, in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement (within group).
Time frame: 12 weeks
To compare changes and differences in fasting lipid profile in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement (within group).
Time frame: 12 weeks
To compare changes and differences in body mass index (BMI), in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement within group.
Time frame: 12 weeks.
To compare changes and differences in body composition (muscle mass(kg), fat mass (kg) and fat in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement within group.
Time frame: 12 weeks.
To compare changes and differences in diabetes quality of life in patients with type 2 diabetes mellitus in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement within group.
Time frame: 12 weeks
To monitor meal replacement related adverse events in participants who are in the intervention group over the study period.
Time frame: 12 weeks
To compare changes and differences in body composition fat mass (kg) in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement vs control group.
Time frame: 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Mar 2025.
- Individual participant dataSharing planned: No
Related trials for Diabetes Mellitus, Type 2
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Nani Draman, Masters principal investigator
Professor
Siti suhaila, Masters study chair
DR
NG Ying ying, Masters study chair
DR
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Meal replacement therapy in people with Diabetes Mellitus, Type 2, run by Hospital Universiti Sains Malaysia at 1 site in Malaysia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Malaysia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact kanmani kumaran, MD (+60135125136, kanmanikumaran@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To compare changes and differences of HbA1c over a 12-week period in patients with uncontrolled type 2 diabetes on oral hypoglycemic agents on meal replacement vs control group. (time frame: 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2025.